{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pathway&page=15", "query": { "intervention": "Pathway", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 1270, "total_pages": 127, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pathway&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pathway&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T14:57:48.406Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002647", "title": "Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Metastatic Cancer" ], "interventions": [ { "name": "verteporfin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "3 Years to 70 Years" }, "enrollment_count": 24, "start_date": "1994-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 2, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002647" }, { "nct_id": "NCT06463028", "title": "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Serabelisib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faeth Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-12-12", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 18, "location_summary": "La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463028" }, { "nct_id": "NCT01158300", "title": "PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "VEGF inhibitor PTC299", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 28, "start_date": "2010-11", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-05-04", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01158300" }, { "nct_id": "NCT00959647", "title": "A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Basal Cell Carcinoma", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-09-03", "completion_date": "2014-01-09", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959647" }, { "nct_id": "NCT05198297", "title": "Safety and Effectiveness of the Hydrus Microstent", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Open Angle Glaucoma", "Primary Open Angle Glaucoma", "Pseudoexfoliation Glaucoma", "Pigmentary Glaucoma" ], "interventions": [ { "name": "Hydrus Microstent", "type": "DEVICE" }, { "name": "Ophthalmic surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 33, "start_date": "2021-12-13", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 5, "location_summary": "Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Zephyrhills", "state": "Florida" }, { "city": "Fraser", "state": "Michigan" }, { "city": "Mason", "state": "Ohio" }, { "city": "Kenosha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05198297" }, { "nct_id": "NCT06401213", "title": "A First-in-Human Safety Trial of MTX-463", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MTX-463", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mediar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 56, "start_date": "2024-04-15", "completion_date": "2024-11-15", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06401213" }, { "nct_id": "NCT02112513", "title": "The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neonatal Respiratory Distress Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 160, "start_date": "2012-11", "completion_date": "2017-06-30", "has_results": false, "last_update_posted_date": "2019-02-28", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 2, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112513" }, { "nct_id": "NCT07775976", "title": "Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Diseases", "Cardiovascular Diseases Risk", "Cardiac Conduction System Disease", "Bundle/Fascicular Abnormalities", "His-Purkinje Disease", "Arrhythmias, Cardiac", "Rhythm Phenotypes", "Myocardial Ischemia", "Syncope", "Syncope Recurrent", "Syncope and Collapse", "Seizure Disorder", "Sleep Apnea Syndrome, Obstructive", "Decision Support Systems, Clinical", "Heart Failure - NYHA II - IV", "Heart Failure (for Example, Fluid Overload)", "HRV", "Cardiopulmonary", "Sudden Cardiac Arrest", "Cardiac Arrest (CA)", "Ventricular Arrhythmias and Cardiac Arrest", "Ventricular Fibrillation", "QT Dispersion", "Atrial Cardiomyopathy" ], "interventions": [ { "name": "COR Wearable ECG Monitoring", "type": "DEVICE" }, { "name": "Cor360 Clinician-Facing Decision-Aid Reporting", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Peerbridge Health, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2026-08-20", "completion_date": "2030-06-17", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 2, "location_summary": "Pasadena, California • Nashville, Tennessee", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07775976" }, { "nct_id": "NCT07783607", "title": "MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Heart Disease Risk Factors" ], "interventions": [ { "name": "Oncology-Embedded Cardiovascular Risk Assessment Pathway", "type": "OTHER" }, { "name": "Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Vermont Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2028-02-01", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783607" }, { "nct_id": "NCT04849364", "title": "Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bryan Schneider, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-08-24", "completion_date": "2024-12-02", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-30T14:57:48.406Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04849364" } ] }